Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?
نویسندگان
چکیده
منابع مشابه
Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?
Pivotal trials on antithrombotic regimens in coronary artery disease have been performed with huge patient cohorts; in CURE, 12 562 patients were randomized, TRITON-TIMI 38 included 13 608 patients, and PLATO 18 624 patients. Such databases provide an extraordinary opportunity to study a treatment effect in several subgroups of patients which—although subsets—still consist of thousands of patie...
متن کاملCrystalloid or colloid for resuscitation. Are we any the wiser?
Introduction In the past year there has been an escalation of the age-old crystalloid–colloid debate as a result of the publication of several systematic reviews assessing the effect of various colloids versus various crystalloids on mortality. In 1998, an excess mortality of 4% for the colloid resuscitated patients was claimed for various colloids versus various crystalloids in various clinica...
متن کاملPost hoc subgroup analysis.
I am surprised by the published conclusions of Hung et al 1 in a recent issue of CHEST (August 2013). The authors’ stated meth ods are not adequate to support their conclusion that hyperimmune IV immunoglobulin (H-IVIG) ben efi ts mortality if given within 5 days to patients with severe 2009 infl uenza A(H1N1) infection. The primary outcome analysis of 34 patients presented in Table 1 of the st...
متن کاملChallenges and Solutions to Pre- and Post-Randomization Subgroup Analyses
Subgroup analyses are commonly performed in the clinical trial setting with the purpose of illustrating that the treatment effect was consistent across different patient characteristics or identifying characteristics that should be targeted for treatment. There are statistical issues involved in performing subgroup analyses, however. These have been given considerable attention in the literatur...
متن کاملPre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
BACKGROUND The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients. OBJECTIVE The purpose of this s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2014
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/ehu202